Phosphodiesterase 4 inhibitors augment the ability of formoterol to enhance glucocorticoid-dependent gene transcription in human airway epithelial cells: A novel mechanism for the clinical efficacy of roflumilast in severe chronic obstructive pulmonary disease

Molecular Pharmacology

Volumn 83, Issue 4, 2013, Pages 894-906

  Moodley, Thunicia ^a   Wilson, Sylvia M ^a   Joshi, Taruna ^a   Rider, Christopher F ^a   Sharma, Pawan ^a   Yan, Dong ^a   Newton, Robert ^a   Giembycz, Mark A ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CD200 ANTIGEN; CILOMILAST; CRISPLD2 PROTEIN; CYCLIC AMP; CYCLIN DEPENDENT KINASE INHIBITOR 1C; DEXAMETHASONE; FLUTICASONE PROPIONATE; FORMOTEROL; GILZ PROTEIN; GLUCOCORTICOID; GSK 256066; LUCIFERASE; N (3,5 DICHLORO 4 PYRIDYL) [1 (4 FLUOROBENZYL) 5 HYDROXY 3 INDOLYL]GLYOXYLIC ACID AMIDE; PHOSPHODIESTERASE INHIBITOR; PROTEIN; RGS2 PROTEIN; ROFLUMILAST; TETOMILAST; UNCLASSIFIED DRUG;

ARTICLE; BRONCHUS MUCOSA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONCENTRATION RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; ENZYME INHIBITION; EPITHELIUM CELL; FEMALE; GENE EXPRESSION REGULATION; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; RESPIRATORY EPITHELIUM; TRANSCRIPTION INITIATION;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AMINOPYRIDINES; BENZAMIDES; CELLS, CULTURED; CYCLOPROPANES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; EPITHELIAL CELLS; ETHANOLAMINES; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; PHOSPHODIESTERASE 4 INHIBITORS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY MUCOSA; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME;

EID: 84875473420     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.083493     Document Type: Article

References (41)

1. Barnes PJ (2008) Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 8:183-192.
2. Bethke TD, Böhmer GM, Hermann R, Hauns B, Fux R, Mörike K, David M, Knoerzer D, Wurst W, and Gleiter CH (2007) Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol 47:26-36.
3. Calverley PM, Martinez FJ, Fabbri LM, Goehring UM, and Rabe KF (2012) Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. Int J Chron Obstruct Pulmon Dis 7:375-382.
4. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, and Martinez FJ; M2-124 and M2-125 study groups (2009) Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 374:685-694.
5. Chang TS, Kim MJ, Ryoo K, Park J, Eom SJ, Shim J, Nakayama KI, Nakayama K, Tomita M, and Takahashi K et al. (2003) p57KIP2 modulates stress-activated signaling by inhibiting c-Jun NH2-terminal kinase/stress-activated protein Kinase. J Biol Chem 278:48092-48098.
6. Clark AR (2007) Anti-inflammatory functions of glucocorticoid-induced genes. Mol Cell Endocrinol 275:79-97.
7. Clark AR and Belvisi MG (2012) Maps and legends: the quest for dissociated ligands of the glucocorticoid receptor. Pharmacol Ther 134:54-67.
8. Dent G, White SR, Tenor H, Bodtke K, Schudt C, Leff AR, Magnussen H, and Rabe KF (1998) Cyclic nucleotide phosphodiesterase in human bronchial epithelial cells: characterization of isoenzymes and functional effects of PDE inhibitors. Pulm Pharmacol Ther 11:47-56.
9. Eddleston J, Herschbach J, Wagelie-Steffen AL, Christiansen SC, and Zuraw BL (2007) The anti-inflammatory effect of glucocorticoids is mediated by glucocorticoid-induced leucine zipper in epithelial cells. J Allergy Clin Immunol 119:115-122.
10. Fuhrmann M, Jahn HU, Seybold J, Neurohr C, Barnes PJ, Hippenstiel S, Kraemer HJ, and Suttorp N (1999) Identification and function of cyclic nucleotide phosphodiesterase isoenzymes in airway epithelial cells. Am J Respir Cell Mol Biol 20: 292-302.
11. Galliher-Beckley AJ and Cidlowski JA (2009) Emerging roles of glucocorticoid receptor phosphorylation in modulating glucocorticoid hormone action in health and disease. IUBMB Life 61:979-986.
12. Giembycz MA and Field SK (2010) Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD. Drug Des Devel Ther 4:147-158.
13. Giembycz MA, Kaur M, Leigh R, and Newton R (2008) A Holy Grail of asthma management: toward understanding how long-acting b(2)-adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids. Br J Pharmacol 153: 1090-1104.
14. Giembycz MA and Newton R (2011) Harnessing the clinical efficacy of phosphodiesterase 4 inhibitors in inflammatory lung diseases: dual-selective phosphodiesterase inhibitors and novel combination therapies. Handb Exp Pharmacol 204: 415-446.
15. Gross NJ, Giembycz MA, and Rennard SI (2010) Treatment of chronic obstructive pulmonary disease with roflumilast, a new phosphodiesterase 4 inhibitor. COPD 7: 141-153.
16. Hatzelmann A, Morcillo EJ, Lungarella G, Adnot S, Sanjar S, Beume R, Schudt C, and Tenor H (2010) The preclinical pharmacology of roflumilast-a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 23:235-256.
17. Hertz AL, Bender AT, Smith KC, Gilchrist M, Amieux PS, Aderem A, and Beavo JA (2009) Elevated cyclic AMP and PDE4 inhibition induce chemokine expression in human monocyte-derived macrophages. Proc Natl Acad Sci USA 106: 21978-21983.
18. Hogg JC (2004) Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 364:709-721.
19. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, and Coxson HO et al. (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350: 2645-2653.
20. Holden NS, Bell MJ, Rider CF, King EM, Gaunt DD, Leigh R, Johnson M, Siderovski DP, Heximer SP, and Giembycz MA et al. (2011) b2-Adrenoceptor agonist-induced RGS2 expression is a genomic mechanism of bronchoprotection that is enhanced by glucocorticoids. Proc Natl Acad Sci USA 108:19713-19718.
21. Holden NS, Rider CF, Bell MJ, Velayudhan J, King EM, Kaur M, Salmon M, Giembycz MA, and Newton R (2010) Enhancement of inflammatory mediator releaseby b2-adrenoceptor agonists in airway epithelial cells is reversed by glucocorticoid action. Br J Pharmacol 160:410-420.
22. Kaur M, Chivers JE, Giembycz MA, and Newton R (2008) Long-acting beta2-adrenoceptor agonists synergistically enhance glucocorticoid-dependent transcription in human airway epithelial and smooth muscle cells. Mol Pharmacol 73:203-214.
23. Kelly MM, King EM, Rider CF, Gwozd C, Holden NS, Eddleston J, Zuraw B, Leigh R, O'Byrne PM, and Newton R (2012) Corticosteroid-induced gene expression in allergen-challenged asthmatic subjects taking inhaled budesonide. Br J Pharmacol 165:1737-1747.
24. Lazzeri N, Belvisi MG, Patel HJ, Yacoub MH, Chung KF, and Mitchell JA (2001) Effects of prostaglandin E2 and cAMP elevating drugs on GM-CSF release by cultured human airway smooth muscle cells. Relevance to asthma therapy. Am J Respir Cell Mol Biol 24:44-48.
25. Lommatzsch M, Cicko S, Müller T, Lucattelli M, Bratke K, Stoll P, Grimm M, Dürk T, Zissel G, and Ferrari D et al. (2010) Extracellular adenosine triphosphate and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 181:928-934.
26. Meja KK, Catley MC, Cambridge LM, Barnes PJ, Lum H, Newton R, and Giembycz MA (2004) Adenovirus-mediated delivery and expression of a cAMP-dependent protein kinase inhibitor gene to BEAS-2B epithelial cells abolishes the antiinflammatory effects of rolipram, salbutamol, and prostaglandin E2: a comparison with H-89. J Pharmacol Exp Ther 309:833-844.
27. Miller AH, Vogt GJ, and Pearce BD (2002) The phosphodiesterase type 4 inhibitor, rolipram, enhances glucocorticoid receptor function. Neuropsychopharmacology 27:939-948.
28. Miller AL, Garza AS, Johnson BH, and Thompson EB (2007) Pathway interactions between MAPKs, mTOR, PKA, and the glucocorticoid receptor in lymphoid cells. Cancer Cell Int 7:3.
29. Mittelstadt PR and Ashwell JD (2001) Inhibition of AP-1 by the glucocorticoidinducible protein GILZ. J Biol Chem 276:29603-29610.
30. Montuschi P, Kharitonov SA, Ciabattoni G, and Barnes PJ (2003) Exhaled leukotrienes and prostaglandins in COPD. Thorax 58:585-588.
31. Moyer ML, Borror KC, Bona BJ, DeFranco DB, and Nordeen SK (1993) Modulation of cell signaling pathways can enhance or impair glucocorticoid- induced gene expression without altering the state of receptor phosphorylation. J Biol Chem 268: 22933-22940.
32. Newton R, Leigh R, and Giembycz MA (2010) Pharmacological strategies for improving the efficacy and therapeutic ratio of glucocorticoids in inflammatory lung diseases. Pharmacol Ther 125:286-327.
33. Perera WR, Hurst JR, Wilkinson TM, Sapsford RJ, Müllerova H, Donaldson GC, and Wedzicha JA (2007) Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 29:527-534.
34. Rennard SI, Calverley PM, Goehring UM, Bredenbröker D, and Martinez FJ (2011) Reduction of exacerbations by the PDE4 inhibitor roflumilast-the importance of defining different subsets of patients with COPD. Respir Res 12:18.
35. Samuelsson MK, Pazirandeh A, Davani B, and Okret S (1999) p57Kip2, a glucocorticoid-induced inhibitor of cell cycle progression in HeLa cells. Mol Endocrinol 13: 1811-1822.
36. Smith SJ, Brookes-Fazakerley S, Donnelly LE, Barnes PJ, Barnette MS, and Giembycz MA (2003) Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am J Physiol Lung Cell Mol Physiol 284: L279-L289.
37. Smith SJ, Cieslinski LB, Newton R, Donnelly LE, Fenwick PS, Nicholson AG, Barnes PJ, Barnette MS, and Giembycz MA (2004) Discovery of BRL 50481 [3-(N,Ndimethylsulfonamido)-4-methyl-nitrobenzene], a selective inhibitor of phosphodiesterase 7: in vitro studies in human monocytes, lung macrophages, and CD81 T-lymphocytes. Mol Pharmacol 66:1679-1689.
38. Snelgrove RJ, Goulding J, Didierlaurent AM, Lyonga D, Vekaria S, Edwards L, Gwyer E, Sedgwick JD, Barclay AN, and Hussell T (2008) A critical function for CD200 in lung immune homeostasis and the severity of influenza infection. Nat Immunol 9:1074-1083.
39. Surjit M, Ganti KP, Mukherji A, Ye T, Hua G, Metzger D, Li M, and Chambon P (2011) Widespread negative response elements mediate direct repression by agonist-liganded glucocorticoid receptor. Cell 145:224-241.
40. Wang ZQ, Xing WM, Fan HH, Wang KS, Zhang HK, Wang QW, Qi J, Yang HM, Yang J, and Ren YN et al. (2009) The novel lipopolysaccharide-binding protein CRISPLD2 is a critical serum protein to regulate endotoxin function. J Immunol 183:6646-6656.
41. Wilson SM, Shen P, Rider CF, Traves SL, Proud D, Newton R, and Giembycz MA (2009) Selective prostacyclin receptor agonism augments glucocorticoid- induced gene expression in human bronchial epithelial cells. J Immunol 183:6788-6799.